Ligand validation:4TNV

NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose

NAG is a Ligand Of Interest in 4TNV designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
4TNV_NAG_E_401	53%	75%	0.14	0.899	0.33	0.63	-	-	0	0	100%	0.9333
4TNV_NAG_A_401	51%	78%	0.157	0.911	0.26	0.62	-	-	0	0	100%	0.9333
4TNV_NAG_R_401	51%	70%	0.156	0.909	0.47	0.67	-	-	0	0	100%	0.9333
4TNV_NAG_B_401	48%	54%	0.15	0.894	0.69	1.07	-	1	0	0	100%	0.9333
4TNV_NAG_T_401	27%	73%	0.189	0.835	0.35	0.68	-	-	0	0	100%	0.9333
4TNV_NAG_C_401	27%	36%	0.197	0.842	0.57	1.93	-	6	0	0	100%	0.9333
4TNV_NAG_D_401	25%	59%	0.204	0.841	0.46	1.1	-	1	0	0	100%	0.9333
4TNV_NAG_Q_401	11%	61%	0.272	0.792	0.68	0.8	-	-	0	0	100%	0.9333
4TNV_NAG_S_401	8%	58%	0.376	0.851	0.36	1.23	-	1	0	0	100%	0.9333
4TNV_NAG_P_401	2%	45%	0.532	0.806	0.52	1.56	-	2	0	0	100%	0.9333
4TNW_NAG_E_401	46%	78%	0.163	0.897	0.26	0.63	-	-	0	0	100%	0.9333
3RI5_NAG_C_400	28%	40%	0.192	0.843	0.37	1.92	-	2	1	0	100%	0.9333
3RIF_NAG_E_400	8%	56%	0.35	0.817	0.46	1.2	-	2	0	0	100%	0.9333
3RHW_NAG_B_400	5%	41%	0.384	0.791	0.57	1.7	-	3	1	0	100%	0.9333
3H0C_NAG_A_794	100%	56%	0.021	0.995	0.61	1.08	-	1	0	0	100%	0.9333
5LDS_NAG_B_1007	100%	67%	0.022	0.995	0.48	0.79	-	-	0	0	100%	0.9333
5O5D_NAG_A_601	100%	65%	0.022	0.994	0.32	0.99	-	1	0	0	100%	0.9333
6MUG_NAG_G_629	100%	76%	0.022	0.994	0.35	0.58	-	-	0	0	100%	0.9333
3GXM_NAG_A_498	100%	45%	0.026	0.992	0.75	1.34	-	2	0	0	100%	0.9333

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.